Business Development Manager at Magstim | Eastern Region | USA | Passionate About TMS Applications in Neuromodulation and Clinical Medicine | Experienced Endocannabinoid Researcher
For those interested in pain research, please see the attached research articles done by Magstim collaborators! 1. Analgesic effect of repetitive transcranial magnetic stimulation (rTMS) in patients with chronic low back pain. Ambriz‐Tututi, M., Alvarado‐Reynoso, B., & Drucker‐Colín, R. (2016). In this open-label, sham-controlled study, participants with chronic lower back pain were randomized to receive active rTMS (n = 44), sham (n = 12), or physical-therapy (n = 26). In the active group high frequency rTMS (20Hz) at 95% resting motor threshold was delivered to the left M1 for 5 sessions in week 1, followed by 8 further session across the 9 months duration of the study. After 1 week of treatment both the rTMS and physical-therapy groups demonstrated a significant reduction in pain levels, as measured on a visual analogue scale (VAS). However, by week 3 the rTMS group showed an 80% reduction in pain levels, which was significantly greater than the pain reduction achieved in the physical-therapy group. These reductions in VAS scores were maintained across the 9 months of the study for both rTMS and physical-therapy. 2. A 5-day course of rTMS before pain onset ameliorates future pain and increases sensorimotor peak alpha frequency. Nahian S Chowdhury, Khandoker Taseen, Alan Chiang, Wei-Ju Chang, Samantha K Millard, David A Seminowicz, and Siobhan M Schabrun Repetitive transcranial magnetic stimulation (rTMS) has shown promise as an intervention for pain. An unexplored research question is whether the delivery of rTMS prior to pain onset might protect against a future episode of prolonged pain. Compared to sham, individuals who received active rTMS subsequently experienced lower pain on chewing and yawning. Although active rTMS increased PAF, the effects of rTMS on pain were not mediated by changes in PAF or CME. This study is the first to show that rTMS delivered prior to pain onset can protect against future pain and associated functional impairment. Thus, rTMS may hold promise as a prophylactic intervention for persistent pain. Please reach out if you have questions on how Magstim TMS could be used in pain research protocols! #neuroscience #neuromodulation #TMS #Pain
Starts Monday 5 August. The Magstim team will be at International Association for the Study of Pain in #Amsterdam engaging in discussions about technologies Magstim offers for #TMS, #EEG and #tDCS. IASP brings together 5,000 scientists, clinicians, and healthcare providers from various pain disciplines to share the latest #pain research and treatment. Visit Magstim booth 307 to meet Matthew Dale and Katerina Georgopoulou to learn about neurotechnology innovations.
